Lundbeck has launched a Phase 2 clinical trial to assess the efficacy, safety, and tolerability of Lu AG13909, a potential first-in-class treatment for Cushing’s disease. “We are pleased to advance this new approach to potentially treating unmet needs in Cushing’s disease, a condition that, when uncontrolled, is debilitating…
Lower urinary cortisol levels at the start of treatment with Recorlev (levoketoconazole) are associated with higher rates of cortisol normalization among people with endogenous Cushing’s syndrome, according to new analyses from a Phase 3 clinical trial. Patients with lower starting cortisol levels also require lower maintenance doses of Recorlev…
Sparrow Pharmaceuticals’ oral small molecule SPI-62, now being called clofutriben, can lower the levels of free cortisol in the urine of people with Cushing’s syndrome caused by a tumor outside the adrenal glands, including those with Cushing’s disease. Unlike other cortisol-lowering medications, which require careful dosing to prevent…
Daily meditation with the help of headband that tracks brain activity and serves as a personal meditation coach may help people with Cushing’s syndrome have less pain and a better experience while recovering from surgery. That’s according to new research presented at the Endocrine Society Annual Meeting (ENDO 2024) in…
CRN04894, now being called atumelnant, quickly lowered urine cortisol levels in five people with ACTH-dependent Cushing’s syndrome taking part in a clinical trial, according to interim study findings. The open-label Phase 1b/2a trial (NCT05804669), which is being conducted at the National Institutes of Health (NIH) in Maryland, still…
People with Cushing’s syndrome, including those with Cushing’s disease, appear to have more heart issues — like poorer heart function and larger ventricles, which are the heart’s lower chambers — compared with other patients with similar cardiovascular risk factors, a study using MRI imaging has found. The heart issues…
Among people with endogenous Cushing’s syndrome whose high blood pressure, or hypertension, dropped after five months on relacorilant, that response was maintained when the patients continued treatment for an additional period of three months. That’s according to new data from the randomized withdrawal phase of the Phase 3…
Blood levels of cortisol or adrenocorticotropic hormone (ACTH) measured one day after pituitary tumor removal surgery independently predicted Cushing’s disease remission after one year, according to a real-world study. Post-surgical remission rates were higher among adults after a first surgery compared with those seen for patients who underwent a second…
About 80% of people with recurrent Cushing’s disease who underwent a second surgery to remove tumors from the brain’s pituitary gland achieved remission, according to a real-world study. These findings show that repeat surgery “emerges as a reliable and safe treatment modality for residual or recurrent Cushing’s disease, offering…
People with Cushing’s syndrome, marked by high levels of cortisol, had altered red blood cell profiles at diagnosis, according to a study of nearly 400 patients and 2,000 matched controls. Among those with Cushing’s disease, a subtype of the syndrome, remission was more likely to occur in people with…
Get regular updates to your inbox.